Estrogen receptors (ER) and progesterone receptors (PR), and HER2 biomarkers are used for the detection and treatment of breast cancer.24,27 Triple negative breast cancers, which account for 10–20% of breast cancers, do not express ER, PR or HER2 receptors.28–30. This evidence concerns the gene ESR1 and breast carcinoma.